SCHEMBL16698148

SCHEMBL16698148

Cc1cccc(-c2ccccc2)c1C(=O)Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.44
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FOLH1 Q04609 1/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
HNF4A P41235 1/20 0.42
HPGD P15428 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
FGFR1 P11362 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR4 P22455 1/20 0.40
FGFR3 P22607 1/20 0.40
BCAT2 O15382 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429144 0.86 ALDH1A1 (0.45) MYCHPGDALDH1A1CA1CA2
SCHEMBL29485413 0.85 FOLH1 (0.53) MYCFABP3FABP4FOLH1PDCD1
SCHEMBL3229734 0.85 FOLH1 (0.53) MYCFABP3FABP4FOLH1PDCD1
SCHEMBL5725387 0.83 SMN1; SMN2 (0.46) MYCFABP3FABP4FOLH1PDCD1
SCHEMBL7343199 0.82 FOLH1 (0.46) FABP3FABP4FOLH1HNF4AHPGD
SCHEMBL17748183 0.81 ALDH1A1 (0.47) MYCFOLH1PDCD1CD274HNF4A
SCHEMBL30728845 0.81 BCAT2 (0.53) MYCFABP3FABP4FOLH1PDCD1
SCHEMBL8572487 0.81 BCAT2 (0.53) MYCFABP3FABP4FOLH1PDCD1
SCHEMBL247778 0.80 ALDH1A1 (0.54) MYCFABP3FABP4HPGDALDH1A1
SCHEMBL29404978 0.79 HNF4A (0.52) FABP3FABP4FOLH1HNF4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors VIROCURA THERAPEUTICS INC (CA) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors EIF2AK2, GTF3C4, GTF3C1 MYC 3936/4885FABP3 3642/4885FABP4 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.